Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy starting to work within the first one to four weeks, though meaningful weight loss typically becomes visible after eight to twelve weeks. The medicine begins reducing appetite from the first dose, but the licensed titration schedule means the full effect builds gradually over several months. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is clinically suitable for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starter dose exists to settle your system, not to treat. At 0.25mg your prescriber is asking your body to get used to semaglutide before the dose moves anywhere near therapeutic levels. Most people notice some reduction in appetite within the first week or two, a smaller-than-usual hunger signal at mealtimes, or finding a portion that once felt normal now feels like enough. If you are curious about how long before Wegovy kicks in and produces those first noticeable changes, the honest answer is that meaningful appetite changes usually become clearer from week two onwards, and our guide on how long semaglutide takes to kick in covers what to expect day by day during that early period. Weight loss at this stage is usually small, sometimes nothing measurable on the scales at all. That is entirely expected. The scale movement comes later.
Side effects tend to be most noticeable here: nausea, occasional loose stools, a general sense of fatigue after the injection day. For many people these are mild and pass within a few days. If you are finding this stage uncomfortable, the Wegovy FAQs cover practical tips, and our aftercare team is available seven days a week.
Every four weeks or so your prescriber steps the dose upward: 0.25mg becomes 0.5mg, then 1.0mg, then 1.7mg. This is where most people begin to see the scales move with some consistency. Appetite suppression becomes more pronounced; gastric emptying slows more noticeably, which means food stays with you longer. A typical pattern is losing one to two pounds a week on average during this phase, though week-to-week variation is completely normal.
The titration pace matters. Rushing it does not accelerate results, it increases the chance of nausea becoming difficult to manage. If you want to understand how long it takes for Wegovy to work across different individuals, the starting conditions (starting weight, metabolic history, diet changes alongside treatment) all play a role. Our clinical team can discuss your specific situation during a consultation.
The 2.4mg dose is where the published trial evidence sits. The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg for 68 weeks alongside lifestyle changes. Average weight loss was around 15% of body weight. That figure comes from a programme measured in months, not weeks. Think of the first four months as setup; months five to seventeen are where the main reduction happens for most people.
Some patients on semaglutide are now prescribed the higher 7.2mg dose, approved by the MHRA in early 2026, which clinical data suggests brings results closer to those seen with tirzepatide. Whether a higher dose is appropriate is a prescriber decision made over time, based on your response and tolerance. The expected weight-loss timeline on Wegovy has more detail on how the 7.2mg data compares.
For those wondering about the total duration before Wegovy produces its full effect, the honest answer from the trial data is around 52–68 weeks for maximum response, with the steepest drop typically between months three and nine. Plateau phases are common and do not mean the medicine has stopped working.
Hitting a plateau after initial progress is one of the most common questions our prescribers hear. It does not automatically mean treatment is failing. Weight loss is rarely linear: hormonal variation, strength training (muscle is denser than fat), water retention and even sleep quality all affect the number on the scale in a given week.
The clinical benchmark to watch is the six-month mark at your maintenance dose. NICE's appraisal of semaglutide (TA875) recommends reviewing whether to continue if body weight loss is under 5% at that point. Before then, a plateau of three or four weeks is normal and not a signal to change anything without speaking to your prescriber first. If you are consistently not losing weight on Wegovy after several months at maintenance dose, the right step is a clinical review, not simply waiting.
One practical note: many people find it easiest to take their weekly injection on the same day each week, some set a phone reminder for a Sunday evening, well before the Monday 12pm cut-off for same-day dispatch from our pharmacy. A consistent routine reduces the chance of a missed or late dose disrupting your progress. If you are ready to explore whether Wegovy is right for you, the first step is a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.